Algernon Pharmaceuticals CEO Christopher Moreau said the company has announced that its subsidiary Algernon NeuroScience has dosed the first subject in the Phase 1 DMT clinical stroke study. Moreau told Proactive this dosing was in the Netherlands where the study is being conducted at the Centre for Human Drug Research in Leiden. The first part of the study will use a single-escalating dose design aimed at identifying a safe and tolerable dose that will not produce psychedelic effects.

Proactive Canada Financial News

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158


Copyright (c) 2023 TheNewswire - All rights reserved.